Genetic variation in mice: modeling disease, pharmacogenetics, and basic biology
Tim Wiltshire
School of PharmacyUniversity of North Carolina
Chapel Hill
How do we efficiently annotate the function of all the genes in the mammalian genome?
Goal: “Genome-wide functional genomics”
What do we know about gene function?
40234 entries in Entrez Gene
19709 genes (49%) have zero linked references
31672 genes (78%) have five or fewer linked references
Fraction of all Citations Accounted for by Highly-Cited Genes
TP53TNFAPOEMTHFRHLA-DRB1IL6ACETGFB1EGFRVEGFA
How should we use the genetic variation in mice as a model for Annotating gene function and discovery in disease status, pharmacogenetics, and basic biology?
Traditional genetics – F2 crosses, recombinant inbred strains (RI), knockouts, transgenics.
Inbred strains – genetic variation of the inbred strains, haplotype mapping.
New RI initiatives - A new set of comprehensive RI strains
Outbred strains – most closely model human populations
F2
Two parental strains are crossed to produce F1 generation. Brother-sister matings of F1 mice produce F2 generation, a random shuffling of parental strains genomes.
Requires a very large set of mice (~200), each genetically unique
Utility of genotype data, which is a huge undertaking for such a large set, is limited to the life of the mouse
RI Two parental strains are crossed to produce
F1 generation. Brother-sister matings are carried out for 20 generations until genomic pattern is fixed.
Each mouse from a given RI line is genetically identical
Genotyping only has to be done once and can be applied to any phenotype
Number of lines and strain crosses available from an RI cross is limited, decreasing the possible resolution in mapping the trait and the number of traits that can be examined
Genetic diversity through mating
Both methods require months or years to define candidate region
Nature Genetics 36:1133, 2004
Mammalian Genome 13:175, 2002
129S1/SvImJ NOD/LtJ
A/J NZO/HlLtJ
C57BL/6J PWK/PhJ
CAST/EiJ WSB/EiJ
Parental Strains
Randomization of Variation through Meiosis
CAST WSBC57BL6 PWKA/J 129S1 NZONOD
Representative CC genome
The CC has many Independent IterationsHigh Statistical Power
X
Infinitely Reproducible
CC Population ~ Human PopulationCC Population ~ Human Population
SNPs Insertion/deletions
20 x 106 1 x 106
50 x 106 4 x 106
Human
CC
CAST/EiJ WSB/EiJC57BL6/J PWK/PhJA/J 129S1/SvIm NZO/HlLtNOD/Lt
Captures 90% of the variation present in the mouse!Captures 90% of the variation present in the mouse!
The variation is randomly distributed across the genome The variation is randomly distributed across the genome (there are no blind spots)(there are no blind spots)
Yang et al. 2007 Nature Genetics 39, 1100
Roberts et al. 2007 Mammalian Genome 18, 473
How should we use the genetic variation in mice as a model for disease status, pharmacogenetics, and basic biology?
Traditional genetics – F2 crosses, recombinant inbred strains (RI), knockouts, transgenics.
Inbred strains – genetic variation of the inbred strains, haplotype mapping. Whole animal studies Cell-based studies – mouse embryonic fibroblasts (MEFs), hepatocytes,
macrophages
New RI initiatives - A new set of comprehensive RI strains
Outbred strains – most closely model human populations
12
Inter-strain phenotypic variance
Hamilton, Frankel (Cell, 2001)Hamilton, Frankel (Cell, 2001)
Clinical Phenotypes
0
5
10
15
20
25
30
35
A/J
CZ
EC
HII
/EiJ
12
9S
1/S
vIm
JN
ZO
/HLLT
JLP
/JB
ALB
/cB
yJ
KK
/HlJ
SEA
/Gn
JD
BA
/2J
PW
D/P
hLG
/JR
IIIS
/JS
M/J
CE/J
MR
L/M
PJ
NZ
B/B
lNJ
CB
A/J
I/Ln
JS
JL/J
PL/J
AK
R/J
C3
H/H
eJ
BU
B/B
nJ
SW
R/J
DD
YN
ON
/LtJ
MA
/MyJ
P/J
WS
B/E
iJB
TB
R_T
+_t
f/FV
B/N
JP
ER
A/E
iJC
58
/JC
57
BL/6
JN
OR
/LTJ
C5
7B
R/c
dJ
NO
D/L
tJN
ZW
/LacJ
Perc
en
t Tim
e in
Cen
ter
FemaleMale
0
10
20
30
40
50
60
70
NO
N/L
tJ
C5
7B
R/c
dJ
DB
A/2
J
C5
8/J
C3
H/H
eJ
LG
/J
CE/J
WS
B/E
iJ
MR
L/M
pJ
SW
R/J
P/J
A/J
RII
IS/J
NZ
O/H
ILtJ
FV
B/N
J
BA
LB
/cB
yJ
BTB
R T
+ t
f/J
BU
B/B
nJ
C5
7B
L/6
J
AK
R/J
PL/J
I/Ln
J
MA
/MyJ
CB
A/J
NO
D/L
tJ
12
9S
1/S
vlm
J
SM
/J
KK
/HIJ
NZ
B/B
INJ
SJL
/J
NZ
W
Pct
Im
mob
ilit
y
FemaleMale
«Open Field Center Time
Tail Suspension Immobility »
0
0.2
0.4
0.6
0.8
1
1.2
PE
RA
/EiJ
C58
/J
C57
L/J
C57
BL/
10J
C57
BL/
6J
BA
LB/c
J
C3H
/HeJ
WS
B/E
iJ
LP/J
NZ
W/L
acJ
CB
A/J
DB
A/2
J
129S
1/S
vIm
J
A/J
C57
BLK
S/J
PL/
J
DB
A/1
J
SE
A/G
nJ
C57
BR
/cdJ
BT
BR
T+
tf/J
AK
R/J
I/LnJ
NZ
B/B
lNJ
SM
/J
strain mean sd
PERA/EiJ 1 0
C58/J 0.8 0.41
C57L/J 0.7 0.47
C57BL/10J 0.6 0.503
C57BL/6J 0.361 0.487
BALB/cJ 0.25 0.444
C3H/HeJ 0.222 0.428
WSB/EiJ 0.214 0.426
LP/J 0.111 0.323
NZW/LacJ 0.111 0.323
CBA/J 0.105 0.315
DBA/2J 0.105 0.315
129S1/SvImJ 0.1 0.308
A/J 0.1 0.308
C57BLKS/J 0.0938 0.296
PL/J 0.0769 0.277
DBA/1J 0.0556 0.236
SEA/GnJ 0.0556 0.236
C57BR/cdJ 0.0526 0.229
BTBR T+ tf/J 0.04 0.2
AKR/J 0 0
I/LnJ 0 0
NZB/BlNJ 0 0
SM/J 0 0
Quantitative Traits
Susceptibility to developing gallstones
C C C C C C C G C C G C G C G C G C G G C C C G G C G C C G GA A A A A A A A A A T A A A A A A A A A A A A T A A A A A A AG G G G G G G G G G A G G G G G G G G G G G G A G G G G G G GA A A A A A A A A A T A A A A A A A A A A A A T A A A A A A AG G G G G G G G G G A G G G G G G G G G G G G A G G G G G G GT T T T T T T T T T T T T T G T G T G G T T T T T T T T T T TG G G G G G G G G G A G G G G G G G G G G G G A G G G G G G GT T T T T T T T T T T T T T G T G T G G T T T T T T T T T T TT T T T T T T T T T C T T T T T T T T T T T T C T T T T T T TT T T T T T T T T T T T T T G T G T G G T T T T T T T T T T TT T T T T T T T T T C T T T T T T T T T T T T C T T T T T T TC C C C C C C C C C C C T C C C C C C C C C C C C C C C C C CT T T T T T T T T T C T T T T T T T T T T T T C T T T T T T TC C C C C C C C C C C C T C C C C C C C C C C C C C C C C C CT T T T T T T T T T A T T T T T T T T T T T T A T T T T T T TC C C C C C C C C C C C T C C C C C C C C C C C C C C C C C CT T T T T T T T T T A T T T T T T T T T T T T A T T T T T T TC C C C C C C C C C T C T C C C C C C C C C C T C C C C C C CC C C C C C C C C C C C T C C C C C C C C C C C C C C C C C CT T T T T T T T T T A T T T T T T T T T T T T A T T T T T T TC C C C C C C C C C T C T C C C C C C C C C C T C C C C C C CC C C C C C C C C C T C T C C C C C C C C C C T C C C C C C CG G G G G G G G G G A G G G G G G G G G G G G A G G G G G G GA A A G A A A G G A G A G A G A G A G G A G A G G A G A A G G
Haplotype Association Mapping
Taking a 3 SNP window consecutively down the genome andasking “do these haplotypes associate with a specific phenotype”?
Chr Pos 129S1/SvImJ A/J AKR/J BALB/cByJ BTBR_T+_tf/J BUB/BnJ C3H/HeJ1 171297027 T C C T C C T1 171297120 G G A G A G G1 171297250 C T T C T T C1 171297364 T C C T C C T1 171297418 G G G G G G G1 171297467 C C T C T C C1 171297468 C C C C C C C
• Inferred haplotype patterns can then be related back to the observed phenotype values across the same set of strains
CTG
ANOVA analysis: Identify associations between shared haplotypes and phenotypes
129S1/SvImJ 120.7 A/J 67.3BALB/cByJ 105.4 AKR/J 84.6C3H/HeJ 120.1 BTBR_T+_tf/J 110.2FVB/NJ 116.5 BUB/BnJ 67.8NZB/BlNJ 165.5 C57BL/6J 71.7NZW/LacJ 130.7 C57BLKS/J 78.6
C57L/J 80CAST/EiJ 67.1CBA/J 85.4CZECHII/EiJ 81.3DBA/2J 63.4I/LnJ 93.4JF1/Ms 88.8MA/MyJ 122.9MOLF/EiJ 81.6MSM/Ms 103.2NOD/LtJ 103PL/J 97RIIIS/J 48.8SEA/GnJ 82SJL/J 76SM/J 94.7SWR/J 91.2
126.4833 84.34783
TCG
log
P
Genome Location
HDL phenotype analysis - measurement of HDL cholesterol levels 34 mouse strains
IH Groups at ApoA2 Locus
0
100
200
TC
(mg
/dl)
CTG TCG129S1/SvImJ 120.7 AKR/J 84.6BALB/cByJ 105.4 BTBR_T+_tf/J 110.2C3H/HeJ 120.1 BUB/BnJ 67.8FVB/NJ 116.5 C57BL/6J 71.7NZB/BlNJ 165.5 C57BLKS/J 78.6NZW/LacJ 130.7 C57L/J 80
CAST/EiJ 67.1CBA/J 85.4CZECHII/EiJ 81.3DBA/2J 63.4I/LnJ 93.4JF1/Ms 88.8MA/MyJ 122.9MOLF/EiJ 81.6MSM/Ms 103.2NOD/LtJ 103PL/J 97RIIIS/J 48.8SEA/GnJ 82SJL/J 76SM/J 94.7SWR/J 91.2
126.4833 85.12273
Inferred Haplotype Groups at ApoA2 locus
0
5
10
15
20
25
30
35
Perc
en
t Tim
e in
Cen
ter
Female
Male
The use of haplotype association mapping to identify clinical QTL (cQTL)
0
50
100
150
200
250
NucleusAccumbens
Amygdala Hippocampus Prefrontal Cortex
Inte
nsit
y L
evel
Hap Group 1
Hap Group 2
**
*
0
5
10
15
20
25
30
1 2
Pct
Tim
e C
en
ter
Haplotype Group
Identification of clinical QTL and expression difference for open field behavior
log
P
Genome Location
Grm7
Whole-genome association analysis of urethane-induced lung adenoma incidence in laboratory inbred mice.The scatter plots were drawn for -log(P) against SNP positions in the chromosomes. The two horizontal gray lines indicate the significance levels of -log(P) = 4.8 and -log(P) = 6.2. The arrows indicate the genomic regions with -log(P) > 4.8. These refined genomic regions with significant associations are within 10 Mb of one or more QTLs (such as Sluc18, Pas1, Sluc23 and Pas10, and Sluc26) for chemically induced lung cancer detected by previous linkage studies.
Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice.Liu et.al. Nature Genetics 38, 888 - 895 (2006)
Whole organism phenotypesgene expressionbiomarkers
identification of biological networks
Anxiety and
Depression
Gene expression analysis
Biomarker analysis
Haplotype association mapping
Clinical phenotypes
What phenotypes can be used?
Gene Expression as a PhenotypeMendelian or complex?
0
200
400
600
800
1000
1200
1400
1600
1800
2000
BALB
/cBy
J
SWR/J
CE/J
NON/L
tJ
BTBR
T +
tf/J
PL/J
FVB/
NJ
SJL/
JSM
/J
C3H/H
eJ
C57B
L/6J
MA/M
yJ
NZO
/HIL
tJ P/J
129S
1/Sv
ImJ
CBA/J
KK/HlJ
BUB/
BnJ
A/J
I/LnJ
NZW
/Lac
J
NOD/L
tJ
C58/
J
AKR/J
C57B
R/cdJ
MRL/
MpJ
RIIIS/
J
WSB
/EiJ
DBA/2
J
Inte
nsit
y
0
500
1000
1500
2000
2500
3000
BA
LB
/cB
yJ
CE/J
NO
N/L
tJ
AK
R/J
C57B
L/6
J
BTB
R_T
+_t
f/J
PL/J
129S
1/S
vIm
J
BU
B/B
nJ
SM
/J
A/J
NO
D/L
tJ
WS
B/E
iJ
I/Ln
J
C58/J
DB
A/2
J
NZ
W/L
acJ
C3H
/HeJ
SW
R/J
MA
/MyJ
CB
A/J
C57B
R/c
dJ
RII
IS/J
KK
/HlJ
FV
B/N
J
P/J
SJL
/J
Inte
nsit
y
«Glutamate transporter (Slc1a1)hippocampus
Catechol-o-methyltransferase (Comt) »hippocampus
Using gene expression differences between strains to identify gene networks
Probe X
1 2 3 4 5 6 7 8 9 10 11 12 13 14 1516 171819 X
- L
og
P
SignificanceThreshold
Chr
Chr1
ChrX
Probe X
Probe Y
Probe Z
Cis - local regulationcis-QTL band
trans-QTL band
Visualizing eQTL Results
Trans - non-local regulation through diffusable factors
Catechol-O-Methyltransferase (COMT) cis-QTL in Nucleus Accumbens
• Haplotype mapping of expression data for COMT probeset expression in nucleus accumbens
0
500
1000
1500
2000
2500
3000
Inte
nsi
ty
1 2Haplotype Group
Cis - local regulationcis-QTL band
trans-QTL band
Visualizing eQTL Results
Trans - non-local regulation through diffusable factors
functionalenrichment
oth
er
kno
wle
dg
e:
exp
ress
ion
, lit
era
ture
, k
no
wn
inte
ract
ion
s, e
tc
Gene Ontology KEGG pathway
functionalenrichment
oth
er
kno
wle
dg
e:
exp
ress
ion
, lit
era
ture
, k
no
wn
inte
ract
ion
s, e
tc
Gene Ontology KEGG pathway
Schema of trans-band analysis
Trans-regulator candidates functionalenrichment
oth
er
kno
wle
dg
e:
exp
ress
ion
, lit
era
ture
, k
no
wn
inte
ract
ion
s, e
tc
Gene Ontology KEGG pathway
GeneID -logP15502 5.3074559 4.66107652 4.4219357 4.40212862 4.3073074 4.30107652 4.2314828 4.12108946 4.09
>transband at chr=3, pos=46,624,006
Biological hypothesis
Putative Regulator
putative targets
Enrichment Analysis
Rank Name logp Description1 C1qa 3.17 complement component 1, q subcomponent, alpha polypeptide2 Gdap10 3.12 ganglioside-induced differentiation-associated-protein 103 1500011K16Rik 3.09 RIKEN cDNA 1500011K16 gene4 4633402C03Rik 3.07 gnf1m29444_at5 Cradd 3.03 CASP2 and RIPK1 domain containing adaptor with death domain6 Onecut1 3.03 one cut domain, family member 17 Npm3 3.01 nucleoplasmin 38 Ccdc22 2.99 DNA segment, Chr X, Immunex 40, expressed9 Gtpbp4 2.95 GTP binding protein 4
10 Rarres1 2.93 retinoic acid receptor responder (tazarotene induced) 111 Bad 2.92 Bcl-associated death promoter12 Gab1 2.89 growth factor receptor bound protein 2-associated protein 113 Mtap 2.87 methylthioadenosine phosphorylase14 Apcs 2.84 serum amyloid P-component15 Pex6 2.80 peroxisomal biogenesis factor 616 Chd8 2.78 chromodomain helicase DNA binding protein 817 Bnip2 2.77 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP218 AA407659 2.71 expressed sequence AA40765919 Ankfy1 2.71 ankyrin repeat and FYVE domain containing 120 Bap1 2.68 Brca1 associated protein 121 Hs3st3b1 2.68 heparan sulfate (glucosamine) 3-O-sulfotransferase 3B122 A430005L14Rik 2.67 RIKEN cDNA A430005L14 gene23 Akt1 2.65 thymoma viral proto-oncogene 124 Myh9 2.63 myosin, heavy polypeptide 9, non-muscle25 Casp3 2.63 caspase 3, apoptosis related cysteine protease
… …
Transband occurrence of “apoptosis”: 5/25 = 20%
Background occurrence of “apoptosis”: 100/6247 = 1.6%
“Enrichment” = 12.5x Significance by hypergeometric
distribution: p < 10-4
Chr 19, 52.7 MB
Interactions between Gsk3b with trans-band targets
*Gray-genes are from trans-band targets
Five candidate regulators from transband in adipose tissue (GO: Integrin signaling)Name Description LOCUSLINK_ACCS4932425I24Rik RIKEN cDNA 4932425I24 gene 320214Cox17 cytochrome c oxidase, subunit XVII assembly protein homolog (yeast) 12856Gsk3b glycogen synthase kinase 3 beta 56637Nr1i2 nuclear receptor subfamily 1, group I, member 2 18171Popdc2 popeye domain containing 2 64082
Known ns-SNP
Known drug targetEnzastaurin
-/A Frame-shifting variation
0
5
10
15
20
25
30
35
A/J
CZ
EC
HII
/EiJ
12
9S
1/S
vIm
JN
ZO
/HLLT
JLP
/JB
ALB
/cB
yJ
KK
/HlJ
SEA
/Gn
JD
BA
/2J
PW
D/P
hLG
/JR
IIIS
/JS
M/J
CE/J
MR
L/M
PJ
NZ
B/B
lNJ
CB
A/J
I/Ln
JS
JL/J
PL/J
AK
R/J
C3
H/H
eJ
BU
B/B
nJ
SW
R/J
DD
YN
ON
/LtJ
MA
/MyJ
P/J
WS
B/E
iJB
TB
R_T
+_t
f/FV
B/N
JP
ER
A/E
iJC
58
/JC
57
BL/6
JN
OR
/LTJ
C5
7B
R/c
dJ
NO
D/L
tJN
ZW
/LacJ
Perc
en
t Tim
e in
Cen
ter
FemaleMale
0
50
100
150
200
250
NucleusAccumbens
Amygdala Hippocampus Prefrontal Cortex
Inte
nsit
y L
evel
Hap Group 1
Hap Group 2
**
*
Integration of phenotype and expression data
0
5
10
15
20
25
30
1 2
Pct
Tim
e C
en
ter
Haplotype Group
In Silico Pharmacogenetics: Warfarin MetabolismGuo et al. Nat Biotechnol. 2006 May; 24(5): 531–536.
Haplotype-based genetic analysis of warfarin metabolites. A representative set of haplotype blocks having the highest correlation with this data set. For each predicted block, the chromosomal location, number of SNPs within a block, its gene symbol and an indicator of gene expression in liver are shown. The haplotype for each strain is represented by a colored block, and is presented in the same order as the phenotypic data in the top panel. The calculated p-value measures the probability that strain groupings within an individual block would have the same degree of association with the phenotypic data by random chance. In the gene expression column, a green square indicates the gene is expressed in liver tissue, while a gray square indicates that it is unknown.
The log-transformation of the measured combined amount of 7-hydroxywarfarin (7-OH) and its glucuronidated metabolite (M8) as a % of the total amount of drug and metabolites for each of 13 inbred strains.
Haplotype Associated Mapping case study
Fig. 1. Serum ALT measured in human volunteers taking daily oral doses of APAP (4g/day). (A) Lines represent per subject daily serum ALT (U/L) values 14 days prior to clinic admission and throughout the 14-day duration of the study. Subjects were considered responders if peak serum ALT reached greater than 1.5-fold higher than the average of their baseline values (average of values obtained for days -14 and 1-3; N = 22). ALT elevations were observed following the start of treatment on day 4 and continued to fall beyond treatment cessation on day 11. (B) Daily ALT (U/L) values of non-responder volunteers receiving APAP treatment were not significantly different from those receiving placebo (N = 9). (C) The peak ALT fold change (over baseline) reached over the course of treatment per subject number is plotted for both non-responder (white bars) and responder (black bars) individuals. Horizontal line represents a 1.5-fold increase over the subject’s pre-treatment baseline.
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humansAlison H. Harrill, Paul B. Watkins, Stephen Su, Pamela K. Ross, David E. Harbourt, Ioannis M. Stylianou, Gary A. Boorman, Mark W. Russo, Richard S. Sackler, Steven C. Harris, , Philip C. Smith , Raymond Tennant, Molly Bogue, Kenneth Paigen, Christopher Harris, Tanupriya Contractor, Timothy Wiltshire, Ivan Rusyn and David W. Threadgill
Genome Research 2009
(A) Representative APAP-treated mice of strains CAST/EiJ, SM/J, C57BL/6J, DBA/2J, and B6C3F1/J showing varying levels of centrilobular necrosis.
(B) A percent necrosis score (mean ± S.E.) of H&E stained liver sections.
(D) Serum ALT levels (mean ± S.E.) in mice sacrificed 24 hours after dosing
Whole-genome association analysis and targeted sequencing determined that polymorphisms in Ly86, Cd44, Cd59a, and Capn8 correlate strongly with liver injury. Variation in the orthologous human gene, CD44, is associated with susceptibility to acetaminophen in two independent cohorts.
0
5
10
15
20
25
30
35
C57
BL/
6J
DB
A/2
J
A/J
AK
R/J
CB
A/J
C3H
/HeJ
HeL
a
% G
FP
Po
siti
ves
1
10
100
1000
10000
100000
25
6
12
8
64
32
16 8 4 2 1
Max / min expression fold-change
Fre
qu
enc
y
0.01%
0.10%
1.00%
10.00%
100.00%
Cellular Genetics
Develop cell-based assay system for MEFsfrom 30 strains.What cell types?
What phenotypes to measure?
Infectability with lentiviral vectors
High content imagingGene expression profiling
a.
c.
Purify MEFs from 30 different strains
Seed in 96 wells and grow inor 1% serum for 72hrs
At end of each timepoint, stain cellswith JC-1 and measure flourescence
with facs
Technical replicates for 1% FBS 24hr
Interday replicates for 1% FBS 24hr
Heritability:64.7%
Interday replicates for 1% FBS 72hr
Strain distribution pattern of mitochondrial membrane potential across 30 different strains
Scatter Plot
cumulative position0 500000000 1000000000 1500000000 2000000000 2500000000
0
1
2
3
4
d.Scatter Plot
cumulative position2141500000 2142000000 2142500000 2143000000 2143500000 2144000000 2144500000 2145000000
0
1
2
3
4
Chromosome 15: Gene name: Fbxl7
Genome scan for mitochondrial membrane potential
0
10000
20000
30000
40000
50000
60000
70000
ctrl siRNA 1 siRNA 2 siRNA 3 siRNA 4
P = 1.02E-08
nm
ol O
2/m
in/1
x10^
6 ce
lls
0.E+00
1.E+04
2.E+04
3.E+04
4.E+04
0 1 2 3 4 5 6 7
tota
l Cel
l #
Days
Growth Curve of siFbxl7 treated MEFs
ctrl siRNA 3
0
20
40
60
80
100
120
140
0 1 2 3 4 5
% in
crea
se
days
Percentage Increase of Mitochondria Superoxide over ctrl siRNA
siRNA knockdown of Fbxl7
P-ampk (Thr 175) P-p53 (Ser15)
total p53
Ctrl siRNA 3
tubulintubulin
total ampka
Ctrl siRNA 3
p21
Ctrl siRNA 3
Effect of huFbxl7 knockdown in cancer cell lines
GM1600(gliobastoma)
LnCAP(prostate)
Colo741(colorectal)
Hs587t(mammary)
mRNA knockdown cell proliferation mito. membrane potential
MEF Cytotoxicity Assay• 32 Inbred MEF Cell Lines• 100 Compounds; 9 concentrations, 4 multiplexed assays• Data capture BD Pathway 435 high content imaging system
3.7 uM Vinblastine-10.41 uM Vinblastine-1 33.3 uM Vinblastine-1
Hoescht G21-0.41 uM Vinblastine-1
Hoescht G19-33.3 uM Vinblastine-1
Hoescht G20-3.7 uM Vinblastine-1
Mito Red G21-0.41 uM Vinblastine-1
Mito Red G20-3.70 uM Vinblastine-1
Mito Red G19-33.3 uM Vinblastine-1
DNA Content, Nuclear Count & Size
Mitochondrial Membrane Potential Changes (Intensity)
CY5 G19-33.3 uM Vinblastine-1
CY5 G20-3.7 uM Vinblastine-1
CY5 G21-0.41 uM Vinblastine-1
FITC G20-3.7 uM Vinblastine-1
FITC G21-0.41 uM Vinblastine-1
FITC G19-33.3 uM Vinblastine-1
Cell Morphology & Permeability
Cytochrome C Localization and Release
0
10
20
30
40
50
60
70
80
-5 -4.5 -4 -3.5 -3 -2.5 -2 -1.5 -1 -0.5
Mill
ions
log[Docetaxel] (mM)
RFU
LP/J
C57BL/6J
C57L/J
CBA/J
MRL/MpJ
NON/ShiLtJ
SEA/GnJ
BUB/BnJ
C57BR/cdJ
CZECHII/EiJ
WSB/EiJ
NOD/ShiLtJ
RIIIS/J
SWR/J
AKR/J
LG/J
I/LnJ
NOR/LtJ
BTBRT+tf/J
SJL/J
DBA/2J
0
10
20
30
40
50
60
70
80
90
-0.1 0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1
Mil
lio
ns
log[Acetaminophen] (mM)
RF
U
LP/J
C57BL/6J
MRL/MpJ
SEA/GnJ
C57BR/cdJ
CZECHII/EiJ
WSB/EiJ
NOD/ShiLtJ
RIIIS/J
AKR/J
CE/J
NZO/HILtJ
LG/J
I/LnJ
NOR/LtJ
SM/J
BALBc/ByJ
BTBRT+tf/J
PL/J
SJL/J
129S1/SvImJ
A/J
DBA/2J
MEF cell viability studies
Alomar blue analysis Whole well measurement
Strain specific phenotypic differences
Summary
Inbred strains can provide genetic variation that models human variation.
The use of a mouse model allows for control of environmental variation.
All phenotypes measured show variability across inbred mouse strains.
Whole organism studies can be used to model disease status.
Cellular genetics can be used for cell function, toxicogenomics, pharmacogenetics.
Future directions
Improve the haplotype map across the inbred strains
Screening drugs and toxicants in cell-based assays
Acknowledgements
GNFSerge BatalovAndrew SuChunlei WuJeff JanesDave DelanoStephen Su
Joe Bass (Northwestern U.)Bev Paigen (JAX)Mat Pletcher (Pfizer)Lisa Tarantino (UNC)Russell Thomas (Hamner Inst)
collaborators
Genome-wide Distribution of Variation
PP